Bambusa prices a $168.9 million IPO for long-acting immune therapies
The biotech priced 10.56 million shares at $16 ahead of its scheduled 30 October Nasdaq debut under BBTX.
Bambusa Therapeutics is taking its immune-disease pipeline to public investors. Its upsized IPO was priced to generate approximately $168.9 million before fees and expenses.
What happened
The company priced 10,555,555 shares at $16 each on 29 October, with Nasdaq trading scheduled to begin on 30 October under BBTX. Settlement was expected on 2 November, subject to customary conditions.
Underwriters also received a 30-day option to buy up to 1,583,333 additional shares. That potential purchase is separate from the base offering’s gross proceeds.
Bambusa develops long-acting bispecific antibodies for immunology and inflammation. A bispecific antibody is designed to bind two targets, potentially combining biological effects within one treatment.
Why it matters
Public capital can help a clinical-stage company fund studies over several years. For a long-acting therapy, the development question includes whether a treatment can provide durable benefit with a practical dosing schedule.
The financing gives the pipeline resources; clinical studies still need to establish safety and effectiveness.
The bigger picture
Pricing, the start of trading and settlement are distinct steps. This item records the offering terms and scheduled debut, rather than assuming that all proceeds had already arrived or drawing a conclusion about first-day share performance.